-
Sanofi in obtaining merger clearance for a high profile swap operation of its 11.4 billion EUR Animal Health business (Merial) for Boehringer Ingelheim’s Consumer Health Care business estimated at 6.7 billion EUR
-
L'Oreal on the 1.15 billion EUR acquisition of YSL Beaute Holding
-
GlaxoSmithKline on a 3.6 billion USD acquisition of control over the dermatological pharmaceuticals manufacturer Stiefel and on various issues, including pharmaceutical and consumer protection matters, pertaining to the operation of GSK subsidiaries in Ukraine
-
Teva Pharmaceutical Industries in obtaining merger and antitrust clearance for transactions with Allergan, Barr, Cephalon, Procter & Gamble, and ratiopharm
-
Sanofi-Aventis on their 2.6 billion USD acquisition of shares in Zentiva
-
Beiersdorf Ukraine on a range of tax, unfair competition, and employment law matters, trademark registration, and licensing
-
Daiichi Sankyo Company Limited in connection with obtaining approval from the competition authority for the 4.6 billion USD acquisition of a controlling block of shares in Ranbaxy Laboratories Limited
-
Ecolab, a leading provider of cleaning, food safety, and health protection products and services, on trademark registration and license agreements
-
Novartis, a Swiss-based global pharmaceuticals manufacturer, in obtaining clearance from the competition authority for their 28.1 billion USD acquisition of a majority stake in Alcon, a global leader in eye care, from Nestlé S.A.
-
Sopharma AD (Bulgaria) on their acquisition of a majority stake in Vitaminy, a Ukrainian pharmaceutical factory, and on various matters, including corporate, compliance, obtaining a license for pharmaceutical production, and on complex contract and trademark litigation with one of their distributors
-
Heel, one of Europe's leading pharmaceutical companies, on a range of matters, including sales and distribution, as well as protection from unfair competition
-
Fapomed SA, a Portuguese producer of medical equipment, in a project involving the engineering and construction of a factory in Ukraine
-
Schering-Plough and Merck in obtaining AMC clearance for their 41.1 billion USD merger resulting in the creation of the second-largest pharmaceutical company in the world
